Dr. Zhang on adaptive phase 3 trial of nivolumab, ipilimumab, and cabozantinib in kidney cancer

The supplemental new drug application is supported by findings from the LITESPARK-005 trial.

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

A Cleveland Clinic study found that TKIs in the neoadjuvant setting are associated with greater use of partial nephrectomy when treating patients diagnosed with renal masses in a solitary kidney.

“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.

The disease-free survival and distant metastasis-free survival benefits observed with adjuvant pembrolizumab in the intent-to-treat population of patients with clear cell renal cell carcinoma extended across all subgroups defined by disease risk, tumor stage, and lymph node involvement.

Patients in the phase 3 LITESPARK-005 trial were randomized to belzutifan or everolimus after receiving both a PD-1/L1 inhibitor and a VEGF-TKI for their renal cell carcinoma.